HomeFranceSofinnova Partners Launches Biovelocita

Sofinnova Partners Launches Biovelocita

Sofinnova Partners

Sofinnova Partners, a life sciences venture capital firm based in Paris, London, and Milan, launched Biovelocita, a Pan European investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.

Biovelocita’s newly formed team will provide a framework for startups, combining direct management, financial backing, and access to Sofinnova’s infrastructure and network. The strategy builds upon the firm’s established track record of nurturing innovative ventures within the healthcare and sustainability sectors. It draws inspiration from the achievements of Italy’s first biotech accelerator, BiovelocITA, co-founded by Gabriella Camboni, Silvano Spinelli and Sofinnova Partners in 2015, which has contributed to the growth of the Italian biotech ecosystem.

Key partners of this initiative include:

  • Gabriella Camboni, Partner, co-founder and CEO of BiovelocITA. She also co-founded two Sofinnova companies, EOS (Ethical Oncology Science), serving as its COO until its acquisition by Clovis Oncology in 2013, and Novuspharma, which was acquired by Cell Therapeutics, Inc. in 2003.
  • Matthieu Coutet, Partner, brings nearly two decades of experience in venture capital and operations, including significant contributions to the launch of biotech startups such as TherAchon and Annapurna Therapeutics, and the founding of AdBio Partners.
  • Alex Leech, Partner, an experienced biopharma company builder and a serial CEO, most recently serving as the founding CEO of Alchemab Therapeutics, which raised an $82m Series A investment round.
  • Zhizhong (Joel) Yao, Partner, a former Principal in the Sofinnova Capital Strategy, and a Kauffman Fellow, instrumental in the launch of several biotech start-ups. Holds a Harvard PhD in Chemical Biology and Systems Biology and did post-doctoral research at the French National Institute of Agricultural Research.

Founded in 1972, Sofinnova Partners is a company builder across the entire value chain of life sciences investments, from seed to later-stage. The venture capital firm has 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management.

VCWire

13/12/2023